CSBio CSBio

X
[{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Ajinomoto Bio-Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Aji Bio Pharma will provide drug product aseptic fill finish services for Humanigen. Lenzilumab, Humanigen’s Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody is being administered as part of a Phase III study for COVID-19 patients.

            Lead Product(s): Lenzilumab

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Humanigen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY